Literature DB >> 6870219

Biliary levels of ceforanide.

D E Kenady, M D Ram.   

Abstract

Ceforanide levels in plasma, gallbladder bile, gallbladder tissue, and common bile duct were studied in 10 patients with normal biliary tracts and in 35 patients with biliary disease at various intervals after intravenous injection of 1 g of the drug. Peak blood levels were obtained within 1 h of administration (mean, 67 +/- 15 micrograms/ml). Patients with a normal bilary tract, as well as patients with chronic cholecystitis and a patent cystic duct, achieved high gallbladder bile levels of ceforanide within 2 h (mean, 76 +/- 25 micrograms/ml) and attained even higher levels by 4 h (mean, 182 +/- 51 micrograms/ml). However, all patients with chronic cholecystitis and an occluded cystic duct had very low drug concentrations in the gallbladder bile (14 +/- 7 micrograms/ml at 2 h). Despite this difference in gallbladder bile levels, ceforanide levels of 21 +/- 3 micrograms/g were achieved at 1 to 3 h in gallbladder tissue in both groups with chronic cholecystitis. The concentration of ceforanide in common bile duct was 149 +/- 59 micrograms/ml at 2 h after administration, with levels over 60 micrograms/ml present from 1 to 4 h after administration. These results indicate that ceforanide reaches high levels in the biliary tract. Its potential value in the prevention and treatment of biliary infections should be assessed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6870219      PMCID: PMC184792          DOI: 10.1128/AAC.23.5.706

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Biliary infections and the chouce of antibiotics.

Authors:  M D Ram; M A Gharavi
Journal:  Am J Gastroenterol       Date:  1974-08       Impact factor: 10.864

2.  Cephalothin levels in human bile.

Authors:  M D Ram; S Watanatittan
Journal:  Arch Surg       Date:  1974-02

3.  Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.

Authors:  R D Smyth; M Pfeffer; A Glick; D R Van Harken; G H Hottendorf
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

4.  Biliary excretion and concentration of cefazolin.

Authors:  M D Ram; S Watanatittan
Journal:  Am J Gastroenterol       Date:  1976-12       Impact factor: 10.864

5.  Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease.

Authors:  K R Ratzan; C Ruiz; G L Irvin
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

6.  Cephalexin levels in human bile in presence of biliary tract disease.

Authors:  J E Sales; M Sutcliffe; F O'Grady
Journal:  Br Med J       Date:  1972-08-19

7.  Cefoperazone concentrations in bile and gall bladder wall after intravenous administration.

Authors:  T Nakamura; I Hashimoto; Y Sawada; J Mikami; E Bekki; S Hirasawa; H Abe; Y Watanabe
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

  7 in total
  1 in total

Review 1.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.